Treace Medical Concepts Inc. (TMCI) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Treace Medical Concepts Inc. (NASDAQ: TMCI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.43 (-12.45% 1D, market cap $329.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TMCI ranks #527 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), TMCI carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 79.8%, and ROIC of -32.4%. By comparison, CLPT (ClearPoint Neuro Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.7M) and ANIK (Anika Therapeutics Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
Per TMCI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001630627), Treace Medical Concepts Inc. generated $212.7M in revenue (+1.6% YoY), -$59.0M in net income, and -$29.5M in free cash flow against $190.6M in total assets and $55.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 62.7 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While TMCI currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.44) and Max Pain ($4.65) forces dealer call-delta covering toward $6.98.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Treace Medical Concepts Inc. (TMCI) dropped -12.45% to $4.43, trading at 59% of its 52-week range ($1.17 – $6.65). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Stock Titan report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Alphatec (ATEC) delivered earnings and revenue surprises of -18.18% and -1.38%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunio
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TMCI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TMCI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Treace Medical Concepts Inc. (TMCI) ranks #527 by composite RQD confidence (40/100, grade D-) and #510 by equity capitalization ($329.1M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with TMCI at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TMCI
ACTIVE
Treace Medical Concepts Inc. | D- | 40/100 | — | 79.8% | -32.4% | -12.45% | $329.1M | Benchmark Subject |
| CLPT ClearPoint Neuro Inc. | E | 19/100 | — | 61.4% | -35.0% | -0.19% | $342.7M | /clpt-vs-tmci → |
| ANIK Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | -3.85% | $291.6M | /anik-vs-tmci → |
| EMBC Embecta Corp. | B | 74/100 | 3.9x | 62.6% | 35.5% | -4.73% | $371.7M | /embc-vs-tmci → |
| MOBI Mobia Medical Inc. | D+ | 53/100 | — | — | — | -6.12% | $375.2M | /mobi-vs-tmci → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Treace Medical Concepts Inc. (TMCI) reported GAAP revenue of $212.7M (+1.6% vs. FY2024 revenue of $209.4M , and +13.7% cumulative change since FY2023) , GAAP net income of -$59.0M, operating cash flow of -$16.0M, and free cash flow of -$29.5M (+39.5% YoY). On the balance sheet, TMCI closed FY2025 with $190.6M in total assets against $55.6M in total debt (Altman Z-Score: 0.90, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $212.7M | -$59.0M | -$16.0M | -$29.5M | $190.6M | $55.6M |
| FY2024 (FY) | 2024-12-31 | $209.4M | -$55.7M | -$37.2M | -$48.8M | $217.1M | $53.3M |
| FY2023 (FY) | 2023-12-31 | $187.1M | -$50.0M | -$34.6M | -$34.6M | — | — |
As of 2026-11-02, Treace Medical Concepts Inc. (NASDAQ: TMCI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.43 (-12.45% 1D, market cap $329.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TMCI ranks #527 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), TMCI carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 79.8%, and ROIC of -32.4%. By comparison, CLPT (ClearPoint Neuro Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.7M) and ANIK (Anika Therapeutics Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
Per TMCI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001630627), Treace Medical Concepts Inc. generated $212.7M in revenue (+1.6% YoY), -$59.0M in net income, and -$29.5M in free cash flow against $190.6M in total assets and $55.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TMCI last traded at $4.43 (-12.45% on volume of 290,599 shares), positioning the stock -0.23% below its 50-day simple moving average ($4.44) and +36.31% above its 200-day simple moving average ($3.25). Across its 52-week range of $1.17 to $6.65, TMCI sits at the 59.5% percentile with a 14-day RSI of 62.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.88 to $4.98).
Why TMCI Stock dropped -12.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, TMCI scores 40 out of 100, equating to a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 6 of 20 (ROIC -32.4%; FCF yield -8.96%), indicating the business is not currently generating returns on invested capital or free cash flow relative to its value. Whale 13F Flow scores 14 of 20, reflecting institutional accumulation and options positioning, the strongest pillar and a potential upside driver if sustained. Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), the weakest signal in the set. Macro Regime Fit scores 9 of 20 (Beta 1.0; sector sensitivity), meaning the stock tracks the broader market without a clear defensive offset. Forensic Balance Sheet scores 8 of 20 (Altman Z 0.9; Piotroski F 4/9; Debt/Equity 0.64), which flags financial fragility. For a prospective investor today, the rating implies that any upside case depends on institutional conviction and a change in cash generation, while the balance sheet and insider signals argue for caution and close monitoring rather than a position built on the current fundamentals.
Treace Medical Concepts Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the company profile, it operates with a market capitalization of $0.3B. The source data does not identify its specific products, customers, or revenue model beyond the sector classification and the reported revenue figures in the SEC financials.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $-54.2M | $-59.0M | N/A | $-29.5M | $10.7M | $55.6M |
| FY 2024 | $209.4M | $-55.7M | $-55.7M | N/A | $-48.8M | $11.3M | $53.3M |
| FY 2023 | $187.1M | $-51.4M | $-50.0M | N/A | $-34.6M | N/A | N/A |
Per the market data, gross margin is 79.8%, operating margin -25.5%, and net margin -27.7%, with ROIC at -32.4%. Per the Roarable RQD rating, the Altman Z-Score is 0.9 and the Piotroski F-Score is 4/9, both consistent with financial stress. Debt/Equity is 0.64 per the forensic balance sheet pillar. Reported operating losses and negative free cash flow persist across the three periods shown.
Per the recent news feed, the most prominent item is a scheduled event: TMCI will discuss third-quarter results at 8 a.m. ET on Nov. 6, which the feed classifies as a catalyst. Several market-wire items (MarketBeat, Simply Wall St, Benzinga) reference the stock crossing above its 50-day moving average and general health care pre-market movement, with one MarketBeat item asking whether it is time to sell. A Stock Titan report notes that an innovation chief disposed of 207 shares and reports holding 634,656 shares, a modest insider reduction. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded.
Real-time company headlines, analyst actions, and sector developments for Treace Medical Concepts Inc. (TMCI) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Treace Medical Concepts Inc. (TMCI) market action, institutional positioning, and fundamental catalysts.
Welcome to the TMCI (Treace Medical Concepts Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on TMCI, but look at what you are paying: current EV/EBITDA multiples with 79.8% gross margins. Unless Treace Medical Concepts Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on TMCI, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.06 (52-wk range $1.17 - $6.65), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).